Wednesday, April 1, 1998
The University Daily Kansan
---
Section A · Page 5
Panel on gays starts Jewish Sex Week
By Sara Anderson
By Sara Anderson
sanderson@kanson.com
Kanson staff writer
Jewish Sex Week kicked off last night with a panel discussion, "Gays and Lesbians: The Jewish Community's Invisible Minority."
The program was held at 8 p.m. at the International Room in the Kansas Union and was sponsored by the Hillet Foundation. The program also included designing an AIDS quilt panel for the national Names Project for display and distribution. Thirteen people attended the free event.
The panel included three speakers from the Jewish Community Relations Bureau/American Jewish Committee; Barb Radov, Helen Cohen and Steve Brown. Myron Slotsky, also a member of the
bureau, moderated the event.
The panelists discussed how homosexuality had been a part of the Jewish religion and lifestyle.
"The main point is to relate to who we are as Jews, lesbians and gays — not to have pity or to react, but to reach out." Radov said.
Serena Gutnik, Sioux Falls, S.D., freshman, said the program was amazing.
"It was wonderful and motivating that I could be an advocate of this without being homosexual," she said. "It's fascinating how they explained being Jewish and gay as one entity."
Panelists shared personal experiences and answered questions from the audience. Cohen said she learned how to understand herself better after learning her son was gay.
"I learned how to come out of my own closet," she said. "We all have our own closets, and I am grateful to him."
Slotsky said the main point was to break down some of the myths that surround gays.
"The Jewish community can include gays and lesbians, and all benefit from working together," he said.
Heather Greene, organizer of the event and Des Moines, Iowa, freshman, said she wanted to present a program that was different from the usual sexuality programs.
"I don't think it's an overdone topic, and I haven't ever seen a program that combined the issues together," she said. "If we know more, the more people understand about people around them."
Bus fans appeal to commission
Transportation and parking plans concern residents
By Jeremy M. Doherty jdoherty@kansan.com Kansan staff writer
A debate about the pros and cons of city-financed public transportation erupted unexpectedly at last night's meeting of the Lawrence City Commission.
Commissioners received a report examining the parking conditions in downtown Lawrence. The report, prepared by a Chamber of Commerce task force, called for improvements to parking lots on Rhode Island and New Hampshire streets. The report also asked the commission to consider solutions to downtown overcrowding, such as a public garage.
When commissioners opened the microphone for public comment, a handful of Lawrence residents instead criticized the five-person board's stance on public transportation.
The Lawrence residents said the commission was attempting to
rush ahead with plans for a parking garage without considering other options.
Frank Janzen, Lawrence resident, said the situation downtown was not serious enough to warrant a garage.
"The thing I am most concerned about is having a three-tiered parking lot by the library," he said. "It's the 300-pound gorilla that no one wants. It would go against the ambiance we have downtown."
Hilda Enoch, Lawrence resident,
said she doubted that a garage would serve the best interests of the community.
"We need to look at what our priorities are here," she said.
Mayor Bonnie Augustine disagreed, saying that the downtown parking problem was not caused only by Lawrence residents.
"I'm convinced that we'd still have a parking concern even if we had an adequate public transportation system," Augustine said. "It's because downtown attracts so many people from out of town."
Augustine also said that any plans for a garage would need more discussion at future commission meetings.
Commissioners agreed to:
CITY COMMISSION
Obtain preliminary engineering services for improving the city-owned parking lots in the 800 blocks of Rhode Island and New Hampshire streets.
Obtain design services for directional signs and brochures to promote and explain the downtown parking system.
- Develop an outline for a Downtown Parking Facilities Advisory Board to handle issues related to downtown parking.
"We're a long way away from building a garage," she said.
After hearing from the residents, the commission directed its staff to look further into the report's recommendations.
Last night's incident came just one day after a local organization announced that it had collected 1,000 signatures in favor of establishing a city-wide bus system in Lawrence. Since March, Citizens for Public Transportation has been pushing for a subsidized program to serve KU students and Lawrence residents and would work in tandem with KU on Wheels.
RECYCLE
ALDARA** (limiquimod) cream 5%
Brief Summary—Consult package insert for full prescribing information.
Alfara™ is the brand name for imipename which is an immune response modifier. Each gram of the 5% cream contains 50 mg of imipename in an off white oil-in water vanishing cream base.
Aldara 5% cream is indicated for the treatment of external genital and perianal warts/condyloma acuminate in adults.
NOTE KIDDY WARNINGS
Allerna cream has not been evaluated for the treatment of urethral, intra vaginal, cervical, rectal, or intrauterian human papilloma viral disease and is not recommended for these conditions.
Local skin reactions such as erythema, erosion, exclamation flushing and edema are common. Should severe local skin reaction occur, the cream should be removed by washing the treatment area with mild soap and water. Treatment with Alaura cream can be resumed after the skin reaction has subsided. There may be a need for repeated application of the cream. Therefore, Alaura cream administration is not recommended until gentle peripheral tissue is faded from any deep drug or surgical treatment. Alaura has the potential to exacerbate inflammatory conditions of the skin.
**Information for Patients**
Patients using Alaura 5% cream should receive the following information and instructions: The application of Alaura 5% cream on the transmission of genital warts is unknown. Alaura 5% cream may worsen condusion and vaginal bleeding. Therefore, consent use is not recommended. The treatment area must be cleaned and also protected by physical isolation. It should be avoided.
The treatment area must not be bandaged or otherwise covered or wrapped to be excavated.
Sexual (genital, anal, oral) contact should be avoided while the cream is on the skin.
It is recommended to use Alaura 5% cream application the treatment area be washed with mild soap and water.
Uncleared warting treats males under the formal shoulder should be refilled and the clean area dried.
Uncleared warting treats males under the formal shoulder should be refilled and the clean area dried.
Carcinogenesis, Mutagenesis, and Impairment of Fertility
Bacterial carcinogenesis in a series of eight different areas including nails, mouse lymphoma, CRI chromosome aberration, human lymphocyte chromosome alteration, SHE transformation, rat and humerous marrow cytogenetics, and mouse domain delineation daily. Detailed administration of imiquimod at rats, taken up to times the recommended human dose on cats has throughout mating, gestation, pationation and lactation, demonstrated no impairment of reproduction.
Pregnancy
Pregnancy Category B. There are no adequate and well-controlled studies of pregnant women. Imiquimod was not found to be teratogenic in rat or rabbit pregnancies. In development, the effects of imiquimod on pregnancy were observed. In developmental studies with offspring of pregnant rats treated with imiquimod (3 times human due), no adverse effects were demonstrated.
Nursing Mothers
If it is known whether typically applied imiquimod is exercised in breast milk.
**Pediatric Care**
Safety and efficacy in patients below the age of 18 years have not been established.
**ADVERSE REACTIONS**
In controlled clinical tests, the most frequently reported adverse reactions were those of local application site reactions; some patients also reported reactive symptoms. These reactions were frequent and more widely applied than 20-week applications. Over the 13-week application studies, 1.3% (4237) of the patients discontinued due to local application site reactions. The incidence and severity of local skin reactions
EXERCISE APPEND
WART SITE REACTION ASSESSED BY INVESTIGATOR
MILD/MODERATE SEVERE
|  | FEMALEES | | MALEES | | FEMALEES | | MALEES |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| | (%) | (%) | (%) | (%) | (%) | (%) | (%) |
| Immediate Impairment | Immediate Impairment | Immediate Impairment | Immediate Impairment | Immediate Impairment | Immediate Impairment | Immediate Impairment | Immediate Impairment |
| Erythema | 61% | 21% | 54% | 22% | 4% | 0% | 4% | 0% |
| Enrosion | 30% | 8% | 29% | 6% | 1% | 0% | 1% | 0% |
| Excoriation/Flaking | 15% | 8% | 25% | 8% | 0% | 0% | 1% | 0% |
| Edema | 15% | 8% | 7% | 1% | 0% | 0% | 1% | 0% |
| Oedema | 15% | 2% | 27% | 8% | 1% | 0% | 0% | 0% |
| Ulceration | 9% | 2% | 7% | 1% | 0% | 0% | 0% | 0% |
| Ulceration | 5% | 1% | 4% | 1% | 3% | 0% | 0% | 0% |
Scabbing | 4% | 0% | 13% | 1% | 0% | 0% | 0% | 0% |
Scabbing | 4% | 0% | 13% | 1% | 0% | 0% | 0% | 0% |
Remote site skin reactions were also reported in female and male patients 30 weeks with imiquimod 9% cream. The severe remote site skin reaction reported for female wereychroma (3%), elevation of the epidermis (14%) and eczema (14%) and menace, erosion (9%), eczema, eczema, induration of the skin, and ulcers (12%).
either events going to be probable or possibly related to Akarta reported by more than 5% of patients are listed below; also included are scarcity,
inflation with wiltments and embolism.
3X/WEEK APPLICATION
FEMALES $5\%$ Imiqimoid (n = 117) Vehicle (n = 103) MALES $5\%$ Imiqimoid (n = 156) Vehicle (n = 158)
APPLICATION SITE DISORDERS
Infection:
Itching 32% 20% 22% 10%
Burning 20% 12% 9% 10%
Pain 8% 2% 2% 1%
Soreness 3% 0% 0% 1%
FUNGAL INFECTION*
SYMPTOMIC REACTIONs:
Headache 11% 3% 2% 1%
Influenza-like symptoms 4% 3% 5% 2%
Mucositis 1% 1% 2% 1%
Infections removal without reward to causality with Alders
Neurological hospitals (NPHs) may have to provide patients related to Alzheimer and Parkinson signs by more than 15% of individuals include: Application Site Disorders, Vart Site Responses, Battery training, hypnotherapy, stimulation, during pain, sensory sensitivity, sensory learning, pain, tenderness, tinnitus, tinnurus) Both as a White fatigue, fever, infarction like symptoms, Central and Peripheral Services System Disorders; Gastoria-Internal Systems disorder; Mucositis-Skeletal System disordures; myalgia.
EVERYONE OWNES THEIR MONITORING
DOSAGE AND ADMINISTRATION
Overdose of 5% cream is unlikely due to minimal peritonitis absorption. However, peritoneal ingestion of 5% cream could result in severe local skin reactions. Hypotension was reported following multiple oral doses of 30 mg of amphotericin and was resulted following oral doses of 10 mg of amphotericin.
ADVANCE AND NORMAL HOURS
Adults can be to apply 3 times per week, prior to normal sleeping hours, and left on the skin for 6-10 hours.
3M Pharmaceuticals
Northridge, CA 91324
7087-511-4556
3M Pharmaceuticals
3M-W3-01 3M Center
St. Paul, MN 55144-1000
Hiding from genital warts won't make them go away.
You can put an end to the warts—and the worry—with ALDARA cream.
ALDARA is a prescription cream both men and women can use at home to treat external genital warts. Just see your doctor for a diagnosis and a prescription, and ALDARA cream can get rid of the warts—so you can stop worrying.
Most common side effects are redness, peeling, and itching where ALDARA cream is applied, which may be caused by the body's immune response to the drug.
ALDARA cream treats external genital warts but is not a cure.The effect of ALDARA cream on the spread of genital warts to partners is unknown. ALDARA cream may weaken condoms and diaphragms when applied before sexual contact.
Please see important product information next to this ad.
Call 1-800-544-1574 to find out more about genital warts and ALDARA cream.
3M Pharmaceuticals 1998
3M Pharmaceuticals